Integer (NYSE:ITGR) Lifted to "Buy" at Bank of America

Integer (NYSE:ITGR - Get Free Report) was upgraded by investment analysts at Bank of America from a "neutral" rating to a "buy" rating in a note issued to investors on Monday, Marketbeat.com reports. The brokerage currently has a $135.00 target price on the medical equipment provider's stock, up from their previous target price of $105.00. Bank of America's price objective suggests a potential upside of 13.69% from the company's previous close.

A number of other equities analysts also recently weighed in on ITGR. CL King began coverage on shares of Integer in a research note on Thursday, March 14th. They set a "buy" rating and a $137.00 target price for the company. Benchmark boosted their target price on Integer from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Thursday, March 28th. Finally, KeyCorp lifted their price target on Integer from $123.00 to $139.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $120.50.

Integer Trading Up 2.6 %

Integer stock traded up $2.97 during mid-day trading on Monday, reaching $118.74. 739,413 shares of the company traded hands, compared to its average volume of 302,142. Integer has a 52-week low of $69.40 and a 52-week high of $120.00. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71. The firm's 50 day moving average price is $110.49 and its 200 day moving average price is $97.38. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of 44.11, a P/E/G ratio of 1.46 and a beta of 1.10.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.05. The business had revenue of $413.15 million for the quarter, compared to analysts' expectations of $409.04 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. The business's revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.11 EPS. On average, analysts anticipate that Integer will post 5.28 earnings per share for the current fiscal year.

Institutional Trading of Integer

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Integer by 0.6% in the first quarter. BlackRock Inc. now owns 6,018,773 shares of the medical equipment provider's stock worth $484,933,000 after purchasing an additional 38,664 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Integer by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,843,992 shares of the medical equipment provider's stock worth $301,484,000 after acquiring an additional 15,300 shares during the period. Victory Capital Management Inc. lifted its holdings in Integer by 8.9% in the third quarter. Victory Capital Management Inc. now owns 1,632,549 shares of the medical equipment provider's stock valued at $128,041,000 after acquiring an additional 133,898 shares during the period. State Street Corp grew its position in Integer by 1.6% during the second quarter. State Street Corp now owns 1,356,627 shares of the medical equipment provider's stock valued at $120,211,000 after buying an additional 21,795 shares during the period. Finally, Macquarie Group Ltd. grew its stake in shares of Integer by 0.3% during the 1st quarter. Macquarie Group Ltd. now owns 972,726 shares of the medical equipment provider's stock valued at $75,386,000 after acquiring an additional 3,361 shares during the period. Hedge funds and other institutional investors own 99.29% of the company's stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.